Comparison of imaging biomarkers for Alzheimer's disease: Amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy

International Journal of Geriatric Psychiatry

Volumn 30, Issue 5, 2015, Pages 505-513

  Tateno, Amane ^a   Sakayori, Takeshi ^a   Kawashima, Yoshitaka ^a   Higuchi, Makoto ^b   Suhara, Tetsuya ^b   Mizumura, Sunao ^c   Mintun, Mark A ^d   Skovronsky, Daniel M ^d   Honjo, Kazuyoshi ^a   Ishihara, Keiichi ^a   Kumita, Shinichiro ^a   Suzuki, Hidenori ^a   Okubo, Yoshiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^d AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; beta amyloid; brain atrophy; cognitive function; positron emission tomography

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; DONEPEZIL; FLORBETAPIR F 18; GALANTAMINE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; ENTORHINAL CORTEX; ENTORHINAL CORTEX ATROPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; VOXEL BASED MORPHOMETRY; ATROPHY; BRIEF PSYCHIATRIC RATING SCALE; CASE CONTROL STUDY; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PSYCHOLOGY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ATROPHY; BIOMARKERS; BRIEF PSYCHIATRIC RATING SCALE; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENTORHINAL CORTEX; ETHYLENE GLYCOLS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY;

EID: 84927038311     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4173     Document Type: Article

References (31)

1. Becker JA, Hedden T, Carmasin J, et al,. 2011. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 69: 1032-1042.
2. Camus V, Payoux P, Barré L, et al,. 2012. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical enviroment. Eur J Nucl Med Mol Imaging 39: 621-631.
3. Choi SR, Golding G, Zhuang Z, et al,. 2009. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50: 1887-1894.
4. Clark CM, Schneider JA, Bedell BJ, et al,. 2011. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305: 275-283.
5. Clark CM, Pontecorvo MJ, Beach TG, et al,. 2012. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 11: 669-678.
6. Cummings JL, Mega M, Gray K, et al,. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
7. Drzezga A, Grimmer T, Henriksen G, et al,. 2009. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72: 1487-1494.
8. Fleisher AS, Chen K, Liu X, et al,. 2011. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68: 1404-1411.
9. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
10. Gosche KM, Mortimer JA, Smith CD, et al,. 2002. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58: 1476-1482.
11. Hirata Y, Matsuda H, Nemoto K, et al,. 2005. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382: 269-274.
12. Homma A, Fukuzawa K, Tsukada Y, et al,. 1992. Development of a Japanese version of Alzheimer's Disease Assessment Scale (ADAS). Jpn J Geriatr Psychiatry 3: 647-655. Japanese
13. Imabayashi E, Matsuda H, Tabira T, et al,. 2013. Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer's disease. Brain Behav 3: 487-493.
14. Ingelsson M, Fukumoto H, Newell KL, et al,. 2004. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62: 925-931.
15. Jack CR Jr, Dickson DW, Parisi JE, et al,. 2002. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58: 750-757.
16. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680.
17. Jack CR Jr, Lowe VJ, Weigand SD, et al,. 2009. Serial PiB and MRI in normal, cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365.
18. Jack CR Jr, Knopman DS, Jaqust WJ, et al,. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
19. Joachim CL, Morris JH, Selkoe DJ,. 1989. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135: 309-319.
20. 11C]PIB uptake in Alzheimer disease. Neurology 67: 1575-1580.
21. Klunk WE, Engler H, Nordberg A, et al,. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55: 306-319.
22. Matsuda H, Mizumura S, Nemoto K, et al,. 2012. Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated Lie algebra improves the diagnosis of probable Alzheimer disease. AJNR Am J Neuroradiol 33: 1109-1114.
23. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
24. Morris JC,. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
25. Maruyama M, Shimada H, Suhara T, et al,. 2013. Imaging of tau pathology in tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 18: 1094-1108.
26. Nagata T, Shinagawa S, Ochiai Y, et al,. 2011. Association between executive dysfunction and hippocampal volume in Alzheimer's disease. Int Psychogeriatr 23: 764-771.
27. 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 53: 902-907.
28. Rinne JO, Någren K,. 2010. Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 19: 291-300.
29. Scheltens P, Fox N, Barkhof F, De Carli C,. 2002. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1: 13-21.
30. Shibuya Y, Kawakatsu S, Hayashi H, et al,. 2013. Comparison of entorhinal cortex atrophy between early-onset and late-onset Alzheimer's disease using the VSRAD, a specific and sensitive voxel-based morphometry. Int J Geriatr Psychiatry 28: 372-376.
31. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al,. 2002. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.